The therascreen®PITX2 RGQ PCR Kit has been developed by therawis diagnostics together with its partner QIAGEN. The therascreen® PITX2 RGQ PCR Kit is CE-certified and commercially available.
The therascreen® PITX2 RGQ PCR Kit a unique DNA methylation test for determination of the percent methylation ratio (PMR) in promoter 2 of the pituitary homeobox transcription factor 2 (PITX2) gene using methylation specific real-time PCR on the Rotor-Gene Q 5-plex HRM instrument. The kit provides reagents optimized for reliable and sensitive determination of the PITX2 methylation status and allows for a clinically validated determination of the PMR cut-off value of 12, which is predictive for the response to adjuvant anthracycline-based chemotherapy with or without endocrine therapy when used to test formalin-fixed, paraffin-embedded (FFPE) tissue samples from lymph node-positive, hormonereceptor-positive and HER2-negative high-risk breast cancer patients.
Key features of the therascreen® PITX2 RGQ PCR Kit are:
- Clinically validated CE-certified IVD according to EU Directive 98/79/ECon in vitro diagnostic medical devices
- Robust and reliable, independent of tumor content
- Simple and efficient workflow with Ready-to-use solutions and reaction mixes
- Sample to Insight within <48 hours
- Automated software using Rotor-Gene AssayManager v2.1 for quick and easy results interpretation
The therascreen® PITX2 RGQ PCR kit is intended for the determination of the percent methylation ratio (PMR) of bisDNA bisulfite converted gDNA extracted from FFPE tissue from high risk breast cancer patients. This PMR will aid the clinicians in the prediction of the response to (neo-)adjuvant anthracycline-based chemotherapy (ANT) in high risk breast cancer patients.
